companydata.dkcompanydata.dk

Kariya Pharmaceuticals ApS: Financial statements 2021

CVR: 39270684

Source: annual report 2021, Danish Business Authority

01/01/2021 – 31/12/2021

Kariya Pharmaceuticals ApS (CVR 39270684) has filed annual accounts for 2021. In 2021, the company reported a gross profit of DKK -2,712,238 and a net result of DKK -3,255,075 compared with DKK -2,207,146 the year before. Equity in the 2021 report amounted to DKK -12,726,499. The company had 1 employee in the financial year.

Gross Profit
DKK -2,712,238
Profit/Loss
DKK -3,255,075
Equity
DKK -12,726,499
Total Assets
DKK 1,051,756
Employees
1

Development

YearRevenueGross ProfitProfit/LossEquityEmployees
2021--2.7 mio.-3.3 mio.-12.7 mio.1
2020--1.5 mio.-2.2 mio.-9.5 mio.2
2019--6.3 mio.-7.3 mio.-7.3 mio.1
2018-00100-

Official annual report

View the official annual report directly on the page with a Pro subscription.

Find more companies like Kariya Pharmaceuticals ApS

Build lead lists with filters on industry, geography, size and financials — and export straight to Excel.

Try the lead list generator

Events in 2021

Thomsen Pharma ApS registered as owner of Kariya Pharmaceuticals ApSSep 16, 2021

As of September 16, 2021, Thomsen Pharma ApS is registered as an owner of Kariya Pharmaceuticals ApS with an ownership share of 5%.

Kariya Pharmaceuticals IVS changes name to Kariya Pharmaceuticals ApSAug 23, 2021

On August 23, 2021, the company changed its name from Kariya Pharmaceuticals IVS to Kariya Pharmaceuticals ApS.

Kariya Pharmaceuticals ApS: The 2020 annual report is outJun 28, 2021

Kariya Pharmaceuticals ApS has published its annual report for 2020. Gross profit came to DKK -1,493,450, and the net result was DKK -2,207,146.

About Kariya Pharmaceuticals ApS

Kariya Pharmaceuticals ApS is a Danish company of the type Anpartsselskab based in København N, founded in 2018. The company is registered under the industry Forskning og eksperimentel udvikling inden for naturvidenskab og teknik. The company was previously named Kariya Pharmaceuticals IVS. The management consists of Christian Hölscher. The board consists of Ian Rodney Laquian (chair), Christian Hölscher, Claus Elsborg Olesen and John Connell. The company's owners include JUMIKA Holdings ApS, Thomsen Pharma ApS and MAC Clinical Research Finance Ltd.. The company has 0 employees (2025). In 2025, the company reported a gross profit of DKK -32,093,186 and a net result of DKK -26,490,250 compared with DKK -2,599,412 the year before. Equity in the 2025 report amounted to DKK -25,206,578.

Source: annual report 2025, Danish Business Authority

Other financial years